Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial

Prior treatment

• Severe Concurrent Diseases:
• Immunosuppressive Therapy:
• Patients who have received immunosuppressive therapy within 30 days prior to enrollment.

Other illness

• Other Malignancies:
• Active or history of other malignancies within the past 5 years, except for non-melanoma skin cancer or in situ carcinoma.
• Any serious or uncontrolled medical condition such as:
• Cardiovascular disease (e.g., recent myocardial infarction, unstable angina, or severe arrhythmia)
• Uncontrolled diabetes or hypertension
• Active infections requiring systemic antibiotics or antivirals
• Known hypersensitivity to any of the components of the treatment regimen (e.g., microwave ablation, Huai Er Granules).
• Other Unspecified Conditions:
• Any other condition or circumstances that, in the investigator's opinion, may interfere with the study or pose a risk to the patient.

Other

• Pregnancy or Breastfeeding:
• Women who are pregnant, breastfeeding, or planning to become pregnant during the study.
• Other Contraindications:
• \-

• Age:
• ≥ 18 years old.
• Diagnosis:
• Histologically or cytologically confirmed IA stage non-small cell lung cancer (NSCLC) that is inoperable.
• ECOG Performance Status:
• 0-2 (Eastern Cooperative Oncology Group performance status).
• Previous Treatment:
• Patients must have received no prior systemic treatment for lung cancer.
• Informed Consent:
• Ability to provide written informed consent and willingness to comply with study requirements.
• Adequate Organ Function:
• Patients must have adequate hepatic, renal, and hematologic function as evidenced by:
• Bilirubin ≤ 1.5 × upper limit of normal (ULN)
• ALT/AST ≤ 2.5 × ULN
• Creatinine clearance ≥ 30 mL/min
• Absolute neutrophil count (ANC) ≥ 1,500 cells/μL